Our Take
Novo's pill advantage is real but temporary: Lilly's next-generation pipeline remains ahead while Novo's CagriSema already failed against Zepbound.
Why it matters
The oral GLP-1 market will determine which company controls the $100B+ obesity drug category as injectable growth plateaus. Early prescription velocity often predicts long-term market share.
Do this week
Pharma analysts: Model Novo's oral advantage as 12-18 months maximum before Lilly's triple-acting drug enters trials.
Wegovy pill sales hit $354M in three months
Novo Nordisk's oral Wegovy generated 2.26 billion Danish kroner ($354 million) in first-quarter sales, nearly double analyst estimates of $181 million (per Jefferies). The drug launched January 5 and has accumulated over 2 million prescriptions.
The company revised its 2026 guidance upward, now expecting sales and operating profit to decline 4-12% versus the previous forecast of 5-13%. Overall adjusted sales beat expectations by 1% while operating income exceeded estimates by 14% (per analyst Michael Leuchten).
Prescription velocity shows Novo's early lead: Wegovy pill captured 18,000 prescriptions in its first full week compared to 5,612 for Lilly's competing Foundayo pill in its third week post-April 9 launch (per Reuters).
Oral drugs decide the GLP-1 winner
Novo has lost ground to Lilly in the injectable market, prompting leadership changes and 9,000 planned layoffs. The oral category represents Novo's best chance to regain market share, with the company launching three months ahead of Lilly's Foundayo.
Clinical trial data favors Novo's positioning: Wegovy pill patients lost more body weight in trials than Foundayo patients, though no head-to-head comparison exists. Lilly counters that Foundayo offers convenience with no empty-stomach requirement.
The competitive window may be narrow. Lilly's triple-acting drug showed success in late-stage diabetes and osteoarthritis trials, while Novo's comparable CagriSema combination failed to match Lilly's Zepbound in February testing.
Pipeline depth matters more than launch speed
Novo's oral success reflects execution on existing semaglutide chemistry rather than innovation breakthrough. The company converted its proven injectable into pill form while Lilly developed an entirely new oral molecule for Foundayo.
Next-generation development tells the real story. Lilly's triple-acting approach targets multiple metabolic pathways simultaneously, potentially offering superior efficacy. Novo's equivalent program lags behind, with CagriSema already demonstrating inferior performance.
Market dynamics favor the company with the strongest pipeline depth, not just first-mover advantage in oral delivery. Prescription growth reflects physician familiarity with semaglutide rather than patient preference for Novo's specific formulation.